PolyPid Ltd (PYPD)

The independent Data Safety Monitoring Board (DSMB) has recommended concluding enrollment in PolyPid Ltd's (NASDAQ: PYPD) SHIELD I Phase 3 study of D-PLEX100 to prevent surgical site infections (SSIs) abdominal tissue surgery. DSMB recommended stopping enrollment upon 950 patients, which is the minimum number of targeted patients in the study protocol The suggestion follows the DSMB review of unblinded efficacy data from the first 750 enrolled patients. The SHIELD I study is designed to demonstr

• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 • Conference Call Scheduled for Today at 8:30 a.m. ET PETACH TIKVA, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that following the independent D

The mean of analysts' price targets for PolyPid Ltd. (PYPD) points to a 288.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

PolyPid (NASDAQ:PYPD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors ...

• Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently • Recruitment Progressing as Planned with Approximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery • Extended Cash Runway into the Second Quarter of 2023 with $15 million Non-Dilutive Secured Term Loan Facility • Strengthened Executive Management Team • Conference Call Scheduled for Today at 8:30 AM ET PETAC

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first ...

Biotech stocks posted weekly declines yet again in the week endingApril 29, takingcues from the weak broader market ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $83.85 per unit.

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operat

Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this y

Presentation evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgeryPETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting, being held on April 23-26, 2022 in Dalla

Secured Loan facility with Kreos Capital Extends Company’s Cash Runway into the Second Quarter of 2023PETACH TIKVA, Israel, April 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company has entered into a secured loan agreement for up to $15 million with Kreos Capital VI (Expert Fund) LP (“Kreos”). Proceeds from the loan will be used to support global commercializat

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $85.42 per unit.

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news ...

Presentation Evaluates Efficacy of D-PLEX100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes announced it will be presenting clinical data at the upcoming SAGES (Society of American Gastrointestinal and Endoscopic Surgeons) 2022 Annual Meeting, being held on March 16-19, 2022 in Denver, Color

Unblinded Interim Analysis Expected in the Second Quarter of 2022PETACH TIKVA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, announced today that the 750th patient has been enrolled into its ongoing pivotal Phase 3 SHIELD I study evaluating D-PLEX100 for the prevention of surgical

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022. Barclays Global Investor Conference: Presentation Date: Wednesday, March 16,

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $84.35 per unit.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces ...

PolyPid (NASDAQ:PYPD) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what ...

• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up• Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery. Expect to Reach 750 Enrolled Patients by End of First Quarter 2022 and Have Unblinded Interim Analysis During the Second Quarter of 2022• Recently Completed Planned 500-Patient Blinded Sample Size Reasses

Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share ...

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a confe

Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Be

Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company’s Executive Vice President and Chief F

A look at the shareholders of PolyPid Ltd. ( NASDAQ:PYPD ) can tell us which group is most powerful. Generally...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Raymond James SB-1 Equity ETF (RYJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $82.41 per unit.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..